Accelerating Early-Phase Oncology Development with IQVIA Biotech Australia



Webinar Date/Time: Tuesday, May 21st, 2024 at 2pm PDT | 5pm EDT | 11pm CEST

Over the past decade, Australia has emerged as the leading destination for early-phase oncology clinical trials. Join us for this insightful webinar as we explore the intersection of early-phase oncology studies, Australia’s potential, and IQVIA’s expertise. Together, we can accelerate clinical development and drive innovation in oncology research.

Register Free:

Event overview

Navigating drug development in oncology is a complex and intensive process. While challenges are common in later phases, early-phase oncology (EPO) studies present their own unique obstacles. If left unaddressed, these challenges can significantly impact the complexity of later stages.

In this upcoming webinar, we’ll delve into the unique challenges encountered by sponsors during clinical development. These challenges span regulatory hurdles, patient recruitment, data quality, and study design. Additionally, we’ll share best practices for addressing EPO study obstacles, ranging from optimizing study design to efficient site selection.

Australia, with its untapped potential, plays a pivotal role in accelerating clinical trials. Our webinar will feature a real-world case study, where we’ll explore a clinical development plan showcasing successful escalation and optimization strategies. Notably, this case study underscores Australia’s significant role in mitigating these challenges.

Three key take-aways

  • Learn about the challenges and barriers in accelerating clinical development and the strategies to overcome these obstacles.
  • Dive into a case study showcasing a clinical development plan that demonstrates successful escalation and optimization strategies. This case study highlights the role of Australia in mitigating challenges.
  • Discover how sponsors can benefit from Australia in accelerating clinical trials. With its globally accepted quality data, financial benefits, and speed advantages, Australia provides essential elements for success to emerging biopharma (EBP) sponsors.


Bryce Davies
Senior Director (Head of JAPAC Early Phase Oncology Academy)

With over 10 years of experience in Early Phase Oncology, Bryce currently leads the Early Phase Oncology strategy and delivery within the JAPAC region. His responsibilities include developing and implementing strategic plans to ensure IQVIA remains at the forefront of oncology product development. He actively engages with key stakeholders, including Early Phase Oncology Investigators and internal Subject Matter Experts.

Bryce is an accomplished professional with expertise in successfully transitioning nine compounds from early research (laboratory) to clinical stages. His work includes handling small molecules and complex biologic agents, as well as initiating dose expansion for six clinical compounds following dose escalation completion. He has delivered clinical studies in alignment with overall Clinical Development Plans and served as the Clinical Operations Lead on various regulatory filing (NDA) teams, successfully delivering two FDA filings.

Bryce received his Master of Science - Pharmacology from the university of Auckland.

Jeffrey Keefer
SVP and Head, Therapeutic Science and Strategy Unit

Jeffrey Keefer MD, PhD is a pediatric hematologist/oncologist with 12 years of faculty experience at the Johns Hopkins University School of Medicine where he was in clinical practice, led basic and clinical research programs and was the co-director of the NIH/Johns Hopkins Pediatric Hematology/Oncology Fellowship program.

Jeff joined IQVIA in 2015 where he served in numerous roles including as the past head of the Pediatric and Rare Disease Center of Excellence and more recently as the leader of the Hematology/Oncology Center of Excellence. In his current role Jeff is overseeing IQVIA’s Therapeutic Science and Strategy Unit which houses IQVIA’s 16 therapeutic centers of excellence. Jeff’s team is focused on helping IQVIA’s customers optimize their drug development across the product lifecycle.

Jeff received his BA in Biology from the University of Virginia and his MD and PhD degrees from Vanderbilt University School of Medicine where his graduate work was in Pharmacology. He completed his residency in Pediatrics and served as Chief Resident at the Johns Hopkins Hospital. He continued there for Fellowship in Pediatric Hematology and Oncology before joining the faculty.

Kate Hogg Call
Executive Director, Clinical Development Operations

Kate Hogg Call is an Executive Director, Clinical Development Operations at Tyra Biosciences. Kate has more than 25 years in clinical development and operations in a variety of leadership roles in both the US and Asia. She is dedicated to advancing clinical research and ensuring seamless collaborations both internally and externally.

Register Free:

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Related Content
© 2024 MJH Life Sciences

All rights reserved.